ReVance Therapeutics Obtains $10,000,000 New Round

  • Feed Type
  • Date
    10/25/2013
  • Company Name
    ReVance Therapeutics
  • Mailing Address
    7555 Gateway Boulevard Newark, CA 94560
  • Company Description
    Revance is developing its lead compound, a topical botulinum toxin based on its cutting-edge drug delivery platforms and low molecular weight botulinum toxin. This product leverages Revance’s platform technologies to enhance patient tolerability of botulinum toxin.
  • Website
    http://www.revance.com
  • Transaction Type
    Debt
  • Transaction Amount
    $10,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.